Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
复制标题
DOI：
10.1016/j.chom.2022.04.014
复制
发表时间：
2022-08-10
影响因子：
30.3
通讯作者：
Liu, Shan-Lu
中科院分区：
文献类型：
--
作者：
Evans, John P.;Zeng, Cong;Qu, Panke;Faraone, Julia;Zheng, Yi-Min;Carlin, Claire;Bednash, Joseph S.;Zhou, Tongqing;Lozanski, Gerard;Mallampalli, Rama;Saif, Linda J.;Oltz, Eugene M.;Mohler, Peter J.;Xu, Kai;Gumina, Richard J.;Liu, Shan-Lu
最近关于SARS-CoV-2 Omicron变异亚系BA.1、BA.1.1和BA.2的报道重新引发了人们对疫苗和感染诱导免疫的潜在逃逸的担忧。我们检查了这些亚系和其他主要变体对来自接种mRNA疫苗和加强接种的个体以及恢复的COVID-19患者（包括感染Omicron的患者）的中和抗体的敏感性。我们发现，所有Omicron亚系，特别是BA.1和BA.1.1，表现出大量的免疫逃逸，这在很大程度上克服了mRNA疫苗加强剂量。虽然Omicron BA.1.1几乎完全逃脱了早期大流行性COVID-19患者血清的中和，并且在较小程度上逃脱了Delta感染患者血清的中和，但BA.1.1对Omicron感染的患者血清敏感。重要的是，所有Omicron亚系，包括BA.2，都被Omicron患者血清中和。这些结果强调了加强疫苗剂量对保护免受所有Omicron变体的重要性，并提供了对Omicron亚系自然感染的免疫力的见解。新出现的SARS-CoV-2 Omicron变种可能威胁现有的COVID-19免疫力。Evans及其同事检查了接种两剂和三剂疫苗的个体和恢复的COVID-19患者对BA.1.1和BA.2变体以及先前SARS-CoV-2变体的免疫力。加强疫苗接种，而不是两剂疫苗或非Omicron感染的患者血清，中和Omicron。
Recent reports of SARS-CoV-2 Omicron variant sub-lineages, BA.1, BA.1.1, and BA.2, have reignited concern over potential escape from vaccine- and infection-induced immunity. We examine the sensitivity of these sub-lineages and other major variants to neutralizing antibodies from mRNA-vaccinated and boosted individuals, as well as recovered COVID-19 patients, including those infected with Omicron. We find that all Omicron sub-lineages, especially BA.1 and BA.1.1, exhibit substantial immune escape that is largely overcome by mRNA vaccine booster doses. While Omicron BA.1.1 escapes almost completely from neutralization by early-pandemic COVID-19 patient sera and to a lesser extent from sera of Delta-infected patients, BA.1.1 is sensitive to Omicron-infected patient sera. Critically, all Omicron sub-lineages, including BA.2, are comparably neutralized by Omicron patient sera. These results highlight the importance of booster vaccine doses for protection against all Omicron variants and provide insight into the immunity from natural infection against Omicron sub-lineages. The emerging SARS-CoV-2 Omicron variants may threaten existing COVID-19 immunity. Evans and colleagues examine immunity against the BA.1.1 and BA.2 variants, as well as prior SARS-CoV-2 variants, in two- and three-dose vaccinated individuals and recovered COVID-19 patients. Booster vaccination, but not two-dose vaccinee or non-Omicron-infected patient sera, neutralizes Omicron.
登录
查看更多内容
影响因子：
8.8
作者：
Cerutti G;Guo Y;Liu L;Liu L;Zhang Z;Luo Y;Huang Y;Wang HH;Ho DD;Sheng Z;Shapiro L
通讯作者：
Shapiro L
影响因子：
64.8
作者：
Plante JA;Liu Y;Liu J;Xia H;Johnson BA;Lokugamage KG;Zhang X;Muruato AE;Zou J;Fontes-Garfias CR;Mirchandani D;Scharton D;Bilello JP;Ku Z;An Z;Kalveram B;Freiberg AN;Menachery VD;Xie X;Plante KS;Weaver SC;Shi PY
通讯作者：
Shi PY
影响因子：
64.8
作者：
Liu J;Chandrashekar A;Sellers D;Barrett J;Jacob-Dolan C;Lifton M;McMahan K;Sciacca M;VanWyk H;Wu C;Yu J;Collier AY;Barouch DH
通讯作者：
Barouch DH
影响因子：
64.5
作者：
Hoffmann M;Krüger N;Schulz S;Cossmann A;Rocha C;Kempf A;Nehlmeier I;Graichen L;Moldenhauer AS;Winkler MS;Lier M;Dopfer-Jablonka A;Jäck HM;Behrens GMN;Pöhlmann S
通讯作者：
Pöhlmann S
影响因子：
64.8
作者：
Mlcochova P;Kemp SA;Dhar MS;Papa G;Meng B;Ferreira IATM;Datir R;Collier DA;Albecka A;Singh S;Pandey R;Brown J;Zhou J;Goonawardane N;Mishra S;Whittaker C;Mellan T;Marwal R;Datta M;Sengupta S;Ponnusamy K;Radhakrishnan VS;Abdullahi A;Charles O;Chattopadhyay P;Devi P;Caputo D;Peacock T;Wattal C;Goel N;Satwik A;Vaishya R;Agarwal M;Indian SARS-CoV-2 Genomics Consortium (INSACOG);Genotype to Phenotype Japan (G2P-Japan) Consortium;CITIID-NIHR BioResource COVID-19 Collaboration;Mavousian A;Lee JH;Bassi J;Silacci-Fegni C;Saliba C;Pinto D;Irie T;Yoshida I;Hamilton WL;Sato K;Bhatt S;Flaxman S;James LC;Corti D;Piccoli L;Barclay WS;Rakshit P;Agrawal A;Gupta RK
通讯作者：
Gupta RK